A Phase I/II Study of ARGX-110 in Patients With Advanced Malignancies Expressing CD70.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 17 Aug 2018
At a glance
- Drugs ARGX 110 (Primary)
- Indications Cancer; Cutaneous T cell lymphoma; Haematological malignancies; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors argenx
- 08 Aug 2018 Planned End Date changed from 1 Aug 2018 to 1 Dec 2018.
- 08 Aug 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2018.
- 04 May 2018 Planned End Date changed from 1 Mar 2018 to 1 Aug 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History